168 related articles for article (PubMed ID: 35689489)
1. A biomarker signature to predict complete response to itacitinib and corticosteroids in acute graft-versus-host disease.
Pratta M; Paczesny S; Socie G; Barkey N; Liu H; Owens S; Arbushites MC; Schroeder MA; Howell MD
Br J Haematol; 2022 Aug; 198(4):729-739. PubMed ID: 35689489
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of itacitinib versus placebo in combination with corticosteroids for initial treatment of acute graft-versus-host disease (GRAVITAS-301): a randomised, multicentre, double-blind, phase 3 trial.
Zeiser R; Socié G; Schroeder MA; Abhyankar S; Vaz CP; Kwon M; Clausen J; Volodin L; Giebel S; Chacon MJ; Meyers G; Ghosh M; Deeren D; Sanz J; Morariu-Zamfir R; Arbushites M; Lakshminarayanan M; Barbour AM; Chen YB
Lancet Haematol; 2022 Jan; 9(1):e14-e25. PubMed ID: 34971577
[TBL] [Abstract][Full Text] [Related]
3. Effective treatment of low-risk acute GVHD with itacitinib monotherapy.
Etra A; Capellini A; Alousi A; Al Malki MM; Choe H; DeFilipp Z; Hogan WJ; Kitko CL; Ayuk F; Baez J; Gandhi I; Kasikis S; Gleich S; Hexner E; Hoepting M; Kapoor U; Kowalyk S; Kwon D; Langston A; Mielcarek M; Morales G; Özbek U; Qayed M; Reshef R; Rösler W; Spyrou N; Young R; Chen YB; Ferrara JLM; Levine JE
Blood; 2023 Feb; 141(5):481-489. PubMed ID: 36095841
[TBL] [Abstract][Full Text] [Related]
4. A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease.
Schroeder MA; Khoury HJ; Jagasia M; Ali H; Schiller GJ; Staser K; Choi J; Gehrs L; Arbushites MC; Yan Y; Langmuir P; Srinivas N; Pratta M; Perales MA; Chen YB; Meyers G; DiPersio JF
Blood Adv; 2020 Apr; 4(8):1656-1669. PubMed ID: 32324888
[TBL] [Abstract][Full Text] [Related]
5. Ruxolitinib-corticosteroid as first-line therapy for newly diagnosed high-risk acute graft versus host disease: study protocol for a multicenter, randomized, phase II controlled trial.
Dou L; Peng B; Li X; Wang L; Jia M; Xu L; Li F; Liu D
Trials; 2022 Jun; 23(1):470. PubMed ID: 35668528
[TBL] [Abstract][Full Text] [Related]
6. Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study.
Naing A; Powderly JD; Nemunaitis JJ; Luke JJ; Mansfield AS; Messersmith WA; Sahebjam S; LoRusso PM; Garrido-Laguna I; Leopold L; Geschwindt R; Ding K; Smith M; Berlin JD
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35288468
[TBL] [Abstract][Full Text] [Related]
7. Itacitinib Population Pharmacokinetics and Exposure-Response in Patients With Acute Graft-Versus-Host Disease.
Chen X; Xun Z; Yuska B; McGee R; Yeleswaram S
J Clin Pharmacol; 2023 May; 63(5):622-632. PubMed ID: 36601737
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Clinical Cardiac Safety of Itacitinib, a JAK1 Inhibitor, in Healthy Participants.
Gong X; Darpo B; Xue H; Punwani N; He K; Barbour AM; Epstein N; Landman R; Chen X; Yeleswaram S
Clin Pharmacol Drug Dev; 2020 Aug; 9(6):677-688. PubMed ID: 31821750
[TBL] [Abstract][Full Text] [Related]
9. Itacitinib prevents xenogeneic GVHD in humanized mice.
Courtois J; Ritacco C; Dubois S; Canti L; Vandenhove B; Seidel L; Daulne C; Caers J; Servais S; Beguin Y; Ehx G; Baron F
Bone Marrow Transplant; 2021 Nov; 56(11):2672-2681. PubMed ID: 34172892
[TBL] [Abstract][Full Text] [Related]
10. The Effect of Renal Impairment on the Pharmacokinetics and Safety of Itacitinib.
Srinivas N; Barbour AM; Epstein N; Zhou G; Petusky S; Xun Z; Yuska B; Marbury T; Chen X; Yeleswaram S; Punwani N
J Clin Pharmacol; 2020 Aug; 60(8):1022-1029. PubMed ID: 32149388
[TBL] [Abstract][Full Text] [Related]
11. A Phase 1/2 Study of the Oral Janus Kinase 1 Inhibitors INCB052793 and Itacitinib Alone or in Combination With Standard Therapies for Advanced Hematologic Malignancies.
Zeidan AM; Cook RJ; Bordoni R; Berenson JR; Edenfield WJ; Mohan S; Zhou G; Asatiani E; Srinivas N; Savona MR
Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):523-534. PubMed ID: 35260349
[TBL] [Abstract][Full Text] [Related]
12. Preclinical characterization of itacitinib (INCB039110), a novel selective inhibitor of JAK1, for the treatment of inflammatory diseases.
Covington M; He X; Scuron M; Li J; Collins R; Juvekar A; Shin N; Favata M; Gallagher K; Sarah S; Xue CB; Peel M; Burke K; Oliver J; Fay B; Yao W; Huang T; Scherle P; Diamond S; Newton R; Zhang Y; Smith P
Eur J Pharmacol; 2020 Oct; 885():173505. PubMed ID: 32861662
[TBL] [Abstract][Full Text] [Related]
13. Effect of Hepatic Impairment on the Pharmacokinetics of Itacitinib.
Barbour AM; Rockich K; Cimino E; Zhou G; Leonetti-Whalen C; Chen X; Yeleswaram S; Epstein N; Punwani N
J Clin Pharmacol; 2021 Jul; 61(7):954-960. PubMed ID: 33434286
[TBL] [Abstract][Full Text] [Related]
14. Pentraxin 3 plasma levels at graft-versus-host disease onset predict disease severity and response to therapy in children given haematopoietic stem cell transplantation.
Dander E; De Lorenzo P; Bottazzi B; Quarello P; Vinci P; Balduzzi A; Masciocchi F; Bonanomi S; Cappuzzello C; Prunotto G; Pavan F; Pasqualini F; Sironi M; Cuccovillo I; Leone R; Salvatori G; Parma M; Terruzzi E; Pagni F; Locatelli F; Mantovani A; Fagioli F; Biondi A; Garlanda C; Valsecchi MG; Rovelli A; D'Amico G
Oncotarget; 2016 Dec; 7(50):82123-82138. PubMed ID: 27893415
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Elafin as a Prognostic Biomarker in Acute Graft-versus-Host Disease.
Zewde MG; Morales G; Gandhi I; Özbek U; Aguayo-Hiraldo P; Ayuk F; Baez J; Chanswangphuwana C; Choe H; DeFilipp Z; Etra A; Grupp S; Hexner EO; Hogan W; Javorniczky NR; Kasikis S; Kitko CL; Kowalyk S; Meedt E; Merli P; Nakamura R; Qayed M; Reshef R; Rösler W; Schechter T; Weber D; Wölfl M; Yanik G; Young R; Levine JE; Ferrara JLM; Chen YB
Transplant Cell Ther; 2021 Dec; 27(12):988.e1-988.e7. PubMed ID: 34474163
[TBL] [Abstract][Full Text] [Related]
16. Ruxolitinib: a potential treatment for corticosteroid refractory acute graft-versus-host disease.
Abedin SM; Hamadani M
Expert Opin Investig Drugs; 2020 May; 29(5):423-427. PubMed ID: 32293938
[TBL] [Abstract][Full Text] [Related]
17. Clinical factors predicting the response of acute graft-versus-host disease to corticosteroid therapy: an analysis from the GVHD Working Group of the Japan Society for Hematopoietic Cell Transplantation.
Murata M; Nakasone H; Kanda J; Nakane T; Furukawa T; Fukuda T; Mori T; Taniguchi S; Eto T; Ohashi K; Hino M; Inoue M; Ogawa H; Atsuta Y; Nagamura-Inoue T; Yabe H; Morishima Y; Sakamaki H; Suzuki R
Biol Blood Marrow Transplant; 2013 Aug; 19(8):1183-9. PubMed ID: 23676716
[TBL] [Abstract][Full Text] [Related]
18. Refractory acute graft-versus-host disease: a new working definition beyond corticosteroid refractoriness.
Mohty M; Holler E; Jagasia M; Jenq R; Malard F; Martin P; Socié G; Zeiser R
Blood; 2020 Oct; 136(17):1903-1906. PubMed ID: 32756949
[TBL] [Abstract][Full Text] [Related]
19. Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host disease.
Al Malki MM; London K; Baez J; Akahoshi Y; Hogan WJ; Etra A; Choe H; Hexner E; Langston A; Abhyankar S; Ponce DM; DeFilipp Z; Kitko CL; Adekola K; Reshef R; Ayuk F; Capellini A; Chanswangphuwana C; Eder M; Eng G; Gandhi I; Grupp S; Gleich S; Holler E; Javorniczky NR; Kasikis S; Kowalyk S; Morales G; Özbek U; Rösler W; Spyrou N; Yanik G; Young R; Chen YB; Nakamura R; Ferrara JLM; Levine JE
Blood Adv; 2023 Sep; 7(17):5189-5198. PubMed ID: 37235690
[TBL] [Abstract][Full Text] [Related]
20. Application of proteomics to graft-versus-host disease: from biomarker discovery to potential clinical applications.
Presland RB
Expert Rev Proteomics; 2017 Nov; 14(11):997-1006. PubMed ID: 28974115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
